From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
Top Cited Papers
- 23 September 2011
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 29 (42), 7229-7241
- https://doi.org/10.1016/j.vaccine.2011.06.094
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue virusesVaccine, 2011
- Immune Response to Dengue Virus and Prospects for a VaccineAnnual Review of Immunology, 2011
- Dengue: a continuing global threatNature Reviews Microbiology, 2010
- Development of sanofi pasteur tetravalent dengue vaccineHuman Vaccines, 2010
- Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis virusesVaccine, 2010
- High stability of yellow fever 17D-204 vaccine: A 12-year restrospective analysis of large-scale productionVaccine, 2007
- Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman PrimatesJournal of Virology, 2004
- High Fidelity of Yellow Fever Virus RNA PolymeraseJournal of Virology, 2004
- Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman PrimatesJournal of Virology, 2000
- Construction of intertypic chimeric dengue viruses by substitution of structural protein genes.Proceedings of the National Academy of Sciences of the United States of America, 1991